Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | COMT | P21964 | 1/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LDLR | P01130 | 1/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031631 | 0.84 | KMT2A (0.40) | HPGDSCOMTPDE3BPDE3ACYP11B1 | |
| SCHEMBL19244954 | 0.83 | CYP2A6 (0.49) | CYP11B1CYP11B2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4030659 | 0.80 | KDM4E (0.54) | HPGDSALDH1A1KDM4ECHEK1MAPT | |
| SCHEMBL1544992 | 0.80 | ALDH1A1 (0.47) | COMTALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL15201281 | 0.80 | TYR (0.43) | ALDH1A1KDM4ECYP1A2MAPTLMNA | |
| SCHEMBL650017 | 0.78 | TSHR (0.56) | ALDH1A1KDM4ETDP1ADORA2BNR1H3 | |
| SCHEMBL858846 | 0.78 | — | — | |
| SCHEMBL19244945 | 0.77 | NPC1 (0.43) | ALDH1A1KDM4ECYP1A2MAPTTDP1 | |
| SCHEMBL8453399 | 0.76 | HPGDS (0.58) | HPGDSCOMTPDE3BPDE3ACYP11B1 | |
| SCHEMBL822807 | 0.75 | HPGDS (0.77) | HPGDSCOMTPDE3BPDE3ACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725493-A2 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | Shenzhen Keye Life Technologies, Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20230146233-A1 | A CLASS OF POLYCYCLIC COMPOUNDS INHIBITING RNA HELICASE DHX33 AND THE APPLICATION THEREOF | SHENZHEN KEYE LIFE TECHNOLOGIES, CO., LTD (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230146233-A1 | A CLASS OF POLYCYCLIC COMPOUNDS INHIBITING RNA HELICASE DHX33 AND THE APPLICATION THEREOF | SHENZHEN KEYE LIFE TECHNOLOGIES, CO., LTD (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230146233-A1 | A CLASS OF POLYCYCLIC COMPOUNDS INHIBITING RNA HELICASE DHX33 AND THE APPLICATION THEREOF | SHENZHEN KEYE LIFE TECHNOLOGIES, CO., LTD (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4089089-A1 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | Shenzhen Keye Life Technologies, Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| WO-2022127199-A1 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | 深圳开悦生命科技有限公司 | 2022-06-23 | — | — | WO | disclosed |
| WO-2022127199-A1 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | 深圳开悦生命科技有限公司 | 2022-06-23 | — | — | WO | disclosed |
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20050119312-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2005-06-02 | — | — | US | disclosed |
| EP-1531810-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6875782-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| US-20040063762-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004004665-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004004655-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
| EP-0125749-B1 | IMIDAZOLYL-PYRIDAZINONES | WARNER-LAMBERT COMPANY (US) | 1988-10-05 | — | — | EP | disclosed |
| US-4521416-A | 4,5-Dihydro-6-[(substituted)-1H-imidazol-4-yl or 5-yl]-3(2H)-pyridazinones and 6-[(substituted)-1H-imidazol-4-yl or 5-yl]-3(2H)-pyridazinones | WARNER-LAMBERT COMPANY (US) | 1985-06-04 | — | — | US | disclosed |
| EP-0125749-A2 | Imidazolyl-pyridazinones | WARNER-LAMBERT COMPANY (US) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063762-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | GLP1R, ZYX, SLC5A2 | HPGDS 3439/4885COMT 3657/4885PDE3B 3712/4885 |
| US-20050119312-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | NPY4R, XDH, GPR119 | HPGDS 3388/4885COMT 3401/4885PDE3B 2576/4885 |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | GPR119, SLC5A2, GLP1R | HPGDS 4019/4885COMT 3289/4885PDE3B 4137/4885 |
| US-20230146233-A1 | A CLASS OF POLYCYCLIC COMPOUNDS INHIBITING RNA HELICASE DHX33 AND THE APPLICATION THEREOF | DHX36, DDX21, DDX3X | HPGDS 881/4885COMT 3578/4885PDE3B 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.